var data={"title":"Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diethylcarbamazine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/44052?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49628440\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anthelmintic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519267\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dosages expressed as diethylcarbamazine citrate; some products may alternatively list dosing according to diethylcarbamazine (base). The ratio of diethylcarbamazine citrate to diethylcarbamazine (base) is approximately 2:1.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Loiasis: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CDC recommendations: </i>8 to 10 mg/kg/day in 3 divided doses for 21 days; patients with symptomatic loiasis and microfilarial loads &ge;8,000 microfilariae/mL should receive apheresis or treatment with albendazole prior to treatment with diethylcarbamazine (CDC 2015). For patients with microfilaria in the blood, some clinicians recommend the following dose-escalating regimen: 50 mg as a single dose on day 1; 50 mg 3 times daily on day 2; 100 mg 3 times daily on day 3; 9 mg/kg/day in 3 divided doses on day 4 to end of treatment course (Parasitic Infections 2013). Repeat courses of treatment may be needed to achieve cure (CDC 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>WHO recommendations:</i> Initial: 1 mg/kg as a single dose on day 1, with doubling of the dose on the next 2 days, then 6 to 9 mg/kg/day in divided doses 3 times daily for 18 days (WHO 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: 300 mg once weekly; continue as long as exposure occurs (CDC 2015; Parasitic Infections 2013; WHO 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphatic filariasis: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CDC recommendations:</i> 6 mg/kg/day as a single dose <b>or</b> 6 mg/kg/day in 3 divided doses for 12 days (14 to 21 days in patients with tropical pulmonary eosinophilia) (CDC 2013). For patients with microfilaria in the blood, some clinicians recommend the following dose-escalating regimen: 50 mg as a single dose on day 1; 50 mg 3 times daily on day 2; 100 mg 3 times daily on day 3; 6 mg/kg/day in 3 divided doses on day 4 to end of treatment course (Parasitic Infections 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>WHO recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Due to <i>W. bancrofti: </i> Initial: 1 mg/kg as a single dose on day 1; increase gradually over 3 days to 6 mg/kg/day, in 3 divided doses for 12 days (WHO 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Due to <i>B. malayi</i> or <i>B. timori: </i> 1 mg/kg as a single dose on day 1; increase gradually over 3 days to 3 to 6 mg/kg/day, in 3 divided doses for 6 to 12 days (WHO 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519268\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dosages expressed as diethylcarbamazine citrate; some products may alternatively list dosing according to diethylcarbamazine (base). The ratio of diethylcarbamazine citrate to diethylcarbamazine (base) is approximately 2:1.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Loiasis: </b>Children and Adolescents: Oral: 8 to 10 mg/kg/day in 3 divided doses for 21 days; patients with symptomatic loiasis and microfilarial loads &ge;8,000 microfilariae/mL should receive apheresis or treatment with albendazole prior to treatment with diethylcarbamazine (CDC 2015; Parasitic Infections 2013; <i>Red Book</i> [AAP] 2015). For patients with microfilaria in the blood, some clinicians recommend starting with a lower dosage (eg, 50 mg/day) with gradual increase over 3 days to 9 mg/kg/day in 3 divided doses on day 4 to end of treatment course (Parasitic Infections 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphatic filariasis: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CDC recommendations:</i> Children &ge;18 months and Adolescents:  6 mg/kg/day as a single dose <b>or</b> 6 mg/kg/day in 3 divided doses for 12 days (14 to 21 days in patients with tropical pulmonary eosinophilia) (CDC 2013; <i>Red Book </i>[AAP] 2015). For patients with microfilaria in the blood, some clinicians recommend starting with a lower dosage (eg 50 mg/day) with gradual increase over 3 days to 6 mg/kg/day in 3 divided doses on day 4 to end of treatment course (Parasitic Infections 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>WHO recommendations: </i>Children &gt;10 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519269\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519254\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Reduce dose in moderate to severe impairment (no specific adjustment is provided) (Adjepon-Yamoah 1982; WHO 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519244\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Diethylcarbamazine is not commercially available in the US; it is available for the treatment of lymphatic filariasis and tropical pulmonary eosinophilia, and for treatment/prevention of loiasis through the Centers for Disease Control (CDC) Drug Service for patients that meet the eligibility criteria in the Investigational New Drug (IND) protocol. For more information, contact the CDC at 404-718-4745, parasites@cdc.gov or visit <a target=\"_blank\" href=\"https://www.cdc.gov/laboratory/drugservice/formulary.html&amp;token=8fUMx+fB4trlY8x/Mo8Y9Ddj5kItZ1H7qlW/e3GJptY28xGubTU0DXWzUi5nl8+CwNhzfAcY95p7Mq5fGdd6Fg==&amp;TOPIC_ID=112050\" target=\"_blank\">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519271\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer after meals (WHO 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519247\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Loiasis: </b>Treatment and prophylaxis of loiasis caused by <i>Loa loa</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lymphatic filariasis: </b>Treatment of lymphatic filariasis caused by <i>Wuchereria bancrofti</i>, <i>Brugia malayi</i>, or <i>Brugia timori</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49630625\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. In patients with circulating microfilaremia, adverse reactions may be more common and severe, particular in patients with a high parasite burden.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Collapse, orthostatic hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Brain disease, coma, dizziness, drowsiness, encephalitis (allergic), fatigue, headache, lethargy, malaise, meningoencephalitis (helminthic), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatitis, Mazzotti reaction, pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adenitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, decreased appetite, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Proteinuria (may be reversible)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Lymphadenitis, lymphangitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Skin edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis, corneal edema, eye disease (inflammatory and degenerative changes of optic nerve and retina with prolonged use), eye pain, increased intraocular pressure, iridocyclitis, lacrimation, optic neuritis, photophobia, punctate keratitis, visual field defect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Seizure (patients with a history of epilepsy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519249\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Patients with onchocerciasis (CDC 2013; CDC 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519250\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Encephalopathy: When treating loiasis, encephalopathy (sometimes fatal), and other severe neurologic adverse reactions may occur; risk is related to the microfilarial load. Microfilarial load must be tested prior to treatment. Use caution if microfilarial load &gt;2,500 microfilariae/mL; patients with microfilarial loads &ge;8,000 microfilariae/mL should have the load reduced through apheresis or treatment with albendazole before initiation of treatment with diethylcarbamazine. Corticosteroid use and/or slow dose escalation has <b>not</b> been shown to decrease the risk of fatal encephalopathy (CDC 2015; CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inflammatory reactions: Use in patients with onchocerciasis may precipitate Mazzotti reaction (pruritus, fever, arthralgia). Inflammatory response occurring in the cornea and retina can result in permanent visual damage (McCarthy 2015). Use is contraindicated in patients with onchocerciasis; possibility of co-infection with onchocerciasis should be excluded prior to initiation of treatment with diethylcarbamazine (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: In patients treated for loiasis, some symptoms of loiasis (eg, Calabar swelling, pruritus) may increase briefly during treatment; concomitant use of antihistamines and corticosteroids during the first week of treatment may decrease these symptoms (CDC 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac disorders: Use with caution in patients with cardiac disorders (WHO 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; dosage reduction recommended (WHO 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precaution:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alkaline urine: Elimination half-life is prolonged and AUC is increased in alkaline urine; dose reductions may be needed in patients with diets that promote urinary alkalinization (Adjepon-Yamoah 1982).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170669\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170666\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=112050&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519248\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use of diethylcarbamazine during pregnancy is not recommended (de Silva 1997; WHO 2006). Filarial infection (<i>W. bancrofti, Loa loa</i>) can be transmitted from mother to fetus during pregnancy (Bal 2015; Momb-Ngoma 2015); eradication of maternal infection prior to pregnancy or delaying treatment until after delivery is recommended (Bal 2015; WHO 2008).  Pregnant women should avoid exposure if traveling to infected areas (McGovern 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49992140\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if diethylcarbamazine is present in breast milk; breastfeeding is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519273\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function at baseline and periodically during treatment; in patients with loiasis, measure microfilarial load prior to treatment; patients with microfilarial loads &ge;8,000 microfilariae/mL treated with albendazole to reduce microfilarial load should have close, frequent monitoring of microfilarial load to confirm reduction before initiation of treatment with diethylcarbamazine (CDC 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519252\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exact mechanism of action is unknown. Proposed mechanisms include platelet-mediated triggering of release of excretory antigen from microfilariae; alterations of prostaglandin metabolism in microfilariae and host endothelial cells that leads to immobilization by inhibition of parasite cholinergic muscle receptors; disruption of microtubule formation; and alterations in helminth surface membranes that result in enhanced killing by the host immune system (deSilva 1997; McCarthy 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49519255\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed (de Silva 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Not significant (McCarthy 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 10 to 12 hours (McCarthy 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 to 2 hours (de Silva 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~50% as unchanged drug; ~10% as metabolite); feces (~10%)<b> (</b>de Silva 1997)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49659814\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Banocide (IN, KW, QA, SA);</li>\n      <li>Camin (BD);</li>\n      <li>DCMC (MY);</li>\n      <li>Decet (IN);</li>\n      <li>Dicarmin (BD);</li>\n      <li>Dicazin (BD);</li>\n      <li>Diethizine (TH);</li>\n      <li>Eofil (IN);</li>\n      <li>Filadec (TH);</li>\n      <li>Filarizide (PH);</li>\n      <li>Hetrazan (IN);</li>\n      <li>Noterine (FR, GR);</li>\n      <li>Notezine (VN);</li>\n      <li>Remazin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7093114\"></a>Adjepon-Yamoah KK, Edwards G, Breckenridge AM, Orme ML, Ward SA. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man. <i>Br J Clin Pharmac</i>. 1982;13(6):829-834.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/7093114/pubmed\" target=\"_blank\" id=\"7093114\">7093114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26225417\"></a>Bal M, Sahu PK, Mandal N, et al. Maternal infection Is a risk factor for Early childhood infection in filariasis. <i>PLoS Negl Trop Dis</i>.2015;9(7):e0003955. doi: 10.1371/journal.pntd.0003955.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/26225417/pubmed\" target=\"_blank\" id=\"26225417\">26225417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Parasites-Loiasis: Resource for Health Professionals. <a href=\"http://www.cdc.gov/parasites/loiasis/health_professionals/\" target=\"_blank\">http://www.cdc.gov/parasites/loiasis/health_professionals/</a>. Updated January 20, 2015. Accessed September 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Parasites- Lymphatic Filariasis: Guidance for Evaluation and Treatment. <a href=\"http://www.cdc.gov/parasites/lymphaticfilariasis/health_professionals/dxtx.html\" target=\"_blank\">http://www.cdc.gov/parasites/lymphaticfilariasis/health_professionals/dxtx.html</a>. Updated June 14, 2013. Accessed September 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9129865\"></a>de Silva N, Guyatt H, Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. <i>Drugs</i>. 1997;53(5):769-788.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/9129865/pubmed\" target=\"_blank\" id=\"9129865\">9129865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drugs for Parasitic Infections. <i>Med Lett Drugs Ther</i>. 2013;11(suppl):e1-e31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17367482\"></a>McGovern LM, Boyce TG, Fischer PR. Congenital infections associated with international travel during pregnancy. <i>J Travel Med</i>. 2007;14(2):117-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/17367482/pubmed\" target=\"_blank\" id=\"17367482\">17367482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCarthy JS, Moore TA. Drugs for helminths. In: Bennett JE, Dolin R, and Blaser MJ, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</i>. 8th ed. Philadelphia, PA: Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25897819\"></a>Mombo-Ngoma G, Mackanga JR, Basra A, et al. Loa loa infection in pregnant women, Gabon. <i>Emerg Infect Dis</i>. 2015;21(5):899a-901. doi: 10.3201/eid2105.141471.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/25897819/pubmed\" target=\"_blank\" id=\"25897819\">25897819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers.  Geneva, Switzerland: World Health Organization; 2006. http://apps.who.int/iris/bitstream/10665/43545/1/9241547103_eng.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stuart MC, Kouimtzi M, Hill SR, eds. WHO Model Formulary 2008. Geneva, Switzerland: World Health ORganizationl 2009. http://www.who.int/selection_medicines/list/WMF2008.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO Model Prescribing Information: Drugs Used in Parasitic Disease. 2nd edition. Geneva, Switzerland, World Health Organization; 1995.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diethylcarbamazine citrate (tablets 100 mg Eisai CO Ltd, Japan) [WHO Public Assessment Report part 4]. Available at  https://extranet.who.int/prequal/sites/default/files/NT002part4v1.pdf. Accessed February 16, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diethylcarbamazine citrate (tablets 100 mg Sanofi-Aventis, France) [WHO Public Assessment Report part 4]. Available at https://extranet.who.int/prequal/sites/default/files/NT001Part4v1.pdf. Accessed February 16, 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 112050 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F49628440\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F49519267\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F49519268\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F49519269\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F49519254\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F49519244\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49519271\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F49519247\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F49630625\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F49519249\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F49519250\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46170669\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46170666\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F49519248\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F49992140\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49519273\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F49519252\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F49519255\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49659814\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/112050|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}